Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
A high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorde...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/8178184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550747746598912 |
|---|---|
| author | Wen-Zhe Kang Bing-Zhi Wang Deng-Feng Li Zhi-Chao Jiang Jian-Ping Xiong Yang Li Peng Jin Xin-Xin Shao Hai-Tao Hu Yan-Tao Tian |
| author_facet | Wen-Zhe Kang Bing-Zhi Wang Deng-Feng Li Zhi-Chao Jiang Jian-Ping Xiong Yang Li Peng Jin Xin-Xin Shao Hai-Tao Hu Yan-Tao Tian |
| author_sort | Wen-Zhe Kang |
| collection | DOAJ |
| description | A high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorded. The results were reviewed by a professional pathologist. The radiologist compared the tumor regression before and after chemotherapy by computed tomography (CT). The survival of all patients was obtained by telephone follow-up. Multivariate Cox regression was used to assess the relationship between overall risk of death and Mandard score, imaging evaluation, and ypN stage. Results. In the Mandard score (4-5) group, the median survival time for PR and ypN0 patients was 68.5 and 76.7 months. While in the Mandard score (1-2) group, the median survival time for PD and ypN3a patients was 15.6 and 14.5 months. Imaging evaluation of tumor regression (PR 68.5 months, SD 27.8 months, and PD 10.2 months) and lymph node remission (ypN0 76.7 months, ypN1 61.6 months, ypN2 18.0 months, ypN3a 18.7 months, and ypN3b 18.3 months) showed improved survival. Mandard score, imaging evaluation, and ypN stage are important prognostic factors affecting prognosis. Conclusion. A high Mandard score does not mean neoadjuvant chemotherapy is ineffective in gastric cancer. Patients with imaging evaluation of tumor regression and ypN stage reduction may benefit from neoadjuvant chemotherapy. |
| format | Article |
| id | doaj-art-214a842f94e244d48541eabc110bfb93 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-214a842f94e244d48541eabc110bfb932025-02-03T06:05:55ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/8178184Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?Wen-Zhe Kang0Bing-Zhi Wang1Deng-Feng Li2Zhi-Chao Jiang3Jian-Ping Xiong4Yang Li5Peng Jin6Xin-Xin Shao7Hai-Tao Hu8Yan-Tao Tian9Department of Pancreatic and Gastric SurgeryDepartment of PathologyDepartment of Diagnostic RadiologyDepartment of Medical OncologyDepartment of Pancreatic and Gastric SurgeryDepartment of Pancreatic and Gastric SurgeryDepartment of Pancreatic and Gastric SurgeryDepartment of Pancreatic and Gastric SurgeryDepartment of Pancreatic and Gastric SurgeryDepartment of Pancreatic and Gastric SurgeryA high Mandard score may indicate the tumor is insensitive to chemotherapy. We analyzed tumor regression and lymph node response under different Mandard scores to assess the impact of Mandard score on prognosis. Methods. Mandard scores and ypN stage of postoperative pathological reports were recorded. The results were reviewed by a professional pathologist. The radiologist compared the tumor regression before and after chemotherapy by computed tomography (CT). The survival of all patients was obtained by telephone follow-up. Multivariate Cox regression was used to assess the relationship between overall risk of death and Mandard score, imaging evaluation, and ypN stage. Results. In the Mandard score (4-5) group, the median survival time for PR and ypN0 patients was 68.5 and 76.7 months. While in the Mandard score (1-2) group, the median survival time for PD and ypN3a patients was 15.6 and 14.5 months. Imaging evaluation of tumor regression (PR 68.5 months, SD 27.8 months, and PD 10.2 months) and lymph node remission (ypN0 76.7 months, ypN1 61.6 months, ypN2 18.0 months, ypN3a 18.7 months, and ypN3b 18.3 months) showed improved survival. Mandard score, imaging evaluation, and ypN stage are important prognostic factors affecting prognosis. Conclusion. A high Mandard score does not mean neoadjuvant chemotherapy is ineffective in gastric cancer. Patients with imaging evaluation of tumor regression and ypN stage reduction may benefit from neoadjuvant chemotherapy.http://dx.doi.org/10.1155/2022/8178184 |
| spellingShingle | Wen-Zhe Kang Bing-Zhi Wang Deng-Feng Li Zhi-Chao Jiang Jian-Ping Xiong Yang Li Peng Jin Xin-Xin Shao Hai-Tao Hu Yan-Tao Tian Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? Canadian Journal of Gastroenterology and Hepatology |
| title | Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? |
| title_full | Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? |
| title_fullStr | Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? |
| title_full_unstemmed | Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? |
| title_short | Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy? |
| title_sort | can gastric cancer patients with high mandard score benefit from neoadjuvant chemotherapy |
| url | http://dx.doi.org/10.1155/2022/8178184 |
| work_keys_str_mv | AT wenzhekang cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT bingzhiwang cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT dengfengli cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT zhichaojiang cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT jianpingxiong cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT yangli cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT pengjin cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT xinxinshao cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT haitaohu cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy AT yantaotian cangastriccancerpatientswithhighmandardscorebenefitfromneoadjuvantchemotherapy |